Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

Neuropsychopharmacology

Volumn 29, Issue 1, 2004, Pages 108-116

  Pimlott, S L ^a   Piggott, M ^b   Owens, J ^a   Greally, E ^b   Court, J A ^b   Jaros, E ^c   Perry, R H ^c   Perry, E K ^b   Wyper, D ^d  

^a WESTERN INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

5 I A 85380; Alzheimer's disease; Dementia with lewy bodies; Nicotinic receptor; Parkinson's disease; Vascular dementia

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; IODINE 125; LIGAND; NICOTINIC AGENT; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; BRAIN TISSUE; CADAVER; CELL DENSITY; CELLULAR DISTRIBUTION; CINGULATE GYRUS; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NERVE FIBER; NERVE TRACT; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRIATE CORTEX; TEMPORAL CORTEX; THALAMUS NUCLEUS; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; AUTORADIOGRAPHY; AZETIDINES; BINDING SITES; BRAIN DISEASES; CASE-CONTROL STUDIES; DEMENTIA, VASCULAR; FEMALE; HUMANS; IODINE ISOTOPES; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; RADIOCHEMISTRY; RECEPTORS, NICOTINIC; TISSUE DISTRIBUTION;

EID: 0346688558     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300302     Document Type: Article

References (58)

1. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992a). Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58: 529-541.
2. 3H]cytisine in the human brain. In: Clarke PBS, Quik M, Adlkofer F, Thurau K (eds). Effects on Biological Systems II. Birkhauser Verlag: Basal, pp 363-369.
3. Ballard CG, Court JA, Piggott M, Johnson M, O'Brien J, McKeith I et al (2002). Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn 11: 461-474.
4. Braak H, Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.
5. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A et al (2000). Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76: 385-388.
6. Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L et al (2002). Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 22: 1208-1217.
7. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001). Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49: 175-184.
8. Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA et al (1997). Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Brain Res Dev Brain Res 101: 93-105.
9. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM et al (1998). Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87: 63-78.
10. Court JA, Martin-Ruiz C, Graham A, Perry E (2000a). Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 20: 281-298.
11. Court JA, Perry EK (1995a). Distribution of nicotinic receptors in the CNS. In: Stone TW (ed). CNS Neurotransmitters and Neuromodulators. CRC Press: London, pp 85-104.
12. Court JA, Perry EK, Spurden D, Griffiths M, Kerwin JM, Morris CM et al (1995b). The role of the cholinergic system in the development of the human cerebellum. Brain Res Dev Brain Res 90: 159-167.
13. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG et al (2000b). Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 98: 79-87.
14. Cross RB (1982). Demonstration of neurofibrillary tangles in paraffin sections: a quick and simple method using a modification of Palmgren's method. Med Lab Sci 39: 67-69.
15. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992). A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.
16. Geula C, Mesulam MM (1996). Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 6: 165-177.
17. Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP et al (2001). Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem 76: 258-268.
18. Graham A, Court JA, Martin-Ruiz CM, Jaros E, Perry R, Volsen SG et al (2002). Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. Neuroscience 113: 493-507.
19. Guan ZZ, Zhang X, Ravid R, Nordberg A (2000). Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74: 237-243.
20. Henderson JM, Dunnett SB (1998). Targeting the subthalamic nucleus in the treatment of Parkinson's disease. Brain Res Bull 46: 467-474.
21. Holladay MW, Dart MJ, Lynch JK (1997). Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40: 4169-4194.
22. Horti AG, Koren AO, Lee KS, Mukhin AG, Vaupel DB, Kimes AS et al (1999). Radiosynthesis and preliminary evaluation of 5-[I-123/125]iodo3-(2(S)- azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. Nucl Med Biol 26: 175-182.
23. Kulak JM, Sum J, Musachio JL, McIntosh JM, Quik M (2002). 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha 4 beta 2 Black star subtypes. J Neurochem 81: 403-406.
24. Lange KW, Wells FR, Jenner P, Marsden CD (1993). Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 60: 197-203.
25. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R et al (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125: 1483-1495.
26. Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y (1995). Neuronal nicotinic receptor subtypes. Ann NY Acad Sci 757: 100-116.
27. Martin-Ruiz C, Court J, Lee M, Piggott M, Johnson M, Ballard C et al (2000). Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neural Scand Suppl 176: 34-41.
28. Martin-Ruiz CM, Court J, Molnar E, Lee M, Gotti C, Mamalaki A et al (1999). Alpha 4 but not alpha 3 and alpha 7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73: 1635-1640.
29. Marubio LM, Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove dA et al (1999). Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398: 805-810.
30. Marutle A, Warpman U, Bogdanovic N, Nordberg A (1998). Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[H-3]epibatidine. Brain Res 801: 143-149.
31. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
32. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS et al (2000). 5-Iodo-A-85380, an alpha 4 beta 2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-649.
33. Musachio JL, Scheffel U, Finley PA, Zhan YG, Mochizuki T, Wagner HN et al (1998). 5-[I-125/123]iodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci 62: L351-L357.
34. Nobili L, Sannita WG (1997). Cholinergic modulation, visual function and Alzheimer's dementia. Vis Res 37: 3559-3571.
35. 3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39: 9-12.
36. Paterson D, Nordberg A (2000). Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111.
37. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D et al (1993). Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79.
38. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG et al (1995). Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64: 385-395.
39. Perry EK, Smith CJ, Court JA, Perry RH (1990a). Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm Park Dis Dement Sect 2: 149-158.
40. 3H]-nicotine receptor binding in human brain: characterization and involvement in cholinergic neuropathlogy. Neurosci Res Commun 5: 117-124.
41. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK (1990b). Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neural Sci 95: 119-139.
42. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N et al (1995). Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374: 65-67.
43. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E et al (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 122(Part 8): 1449-1468.
44. Piggott MA, Owens J, O'Brien J, Colloby S, Fenwick J, Wyper D et al (2003). Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 25: 161-173.
45. Quik M, Okihara M, Forno L, Musachio JL (2002). The in vivo imaging ligand iodo-A-85380 and radiolabeled epibatidine bind to similar nicotinic receptor sites in human control and Parkinson disease brains in vitro, programme no. 887.12. 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC. Online.
46. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P (1991). A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 547: 167-170.
47. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM (1998). Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121: 2249-2257.
48. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986). Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46: 288-293.
49. Sihver W, Gillberg PG, Nordberg A (1998). Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [H-3](-)nicotine, [H-3]cytisine and [H-3]epibatidine in vitro autoradiography. Neuroscience 85: 1121-1133.
50. 125I] alpha-bungarotoxin binding. J Chem Neuroanat 13: 105-113.
51. Warpman U, Nordberg A (1995). Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6: 2419-2423.
52. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J et al (1999). Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11: 2551-2565.
53. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol Pharmacol 57: 913-925.
54. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 38: 720-723.
55. Wonnacott S (1997). Presynaptic nicotinic ACh receptors. Trends Neurosci 20: 92-98.
56. Xuereb JH, Perry EK, Candy JM, Bonham JR, Perry RH, Marshall E (1990). Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease. J Neurol Sci 99: 185-197.
57. 123I]iodo-3- (2azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol 28: 91-96.
58. Zoli M, Lena C, Picciotto MR, Changeux JP (1998). Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 18: 4461-4472.